ESR2 and hepatocellular carcinoma: However, it has also been reported that E2 significantly inhibited the malignant behaviors of hepatocellular carcinoma cells through E2/ERβ pathway-mediated upregulation of the NLRP3 inflammasome (Wei et al., 2015).